首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study
【24h】

Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study

机译:同时测定人血浆和尿液中匹伐他汀及其内酯代谢物的简单LC-MS / MS方法,包括抑制血浆中匹伐他汀内酯向匹伐他汀转化的方法及其在药代动力学研究中的应用

获取原文
获取原文并翻译 | 示例
       

摘要

Sometimes, drugs and their metabolites in plasma may convert to each other. This phenomenon is called interconversion, which may result in the instability problem of the plasma samples. The instability problem caused by interconversion of the co-existing metabolites may often be ignored, since there is no drug metabolite in the quality control samples prepared for method validation. Pitavastatin lactone (Pi-LAC), a main metabolite of pitavastatin (Pi), is very unstable and easily converted to Pi in plasma. In this paper, simple and rapid LC-ESI-MS/MS methods were developed for the simultaneous determination of Pi and Pi-LAC in human plasma and urine. The sample stability was examined under different conditions. The interconversion of Pi and Pi-LAC was prevented by adding a pH 4.2 buffer solution to the freshly collected plasma samples. Detection was performed using an electrospray ionization (ESI) operating in positive ion multiple reaction monitoring mode by monitoring the ion transitions from m/. z 422.2→290.3 (Pi), 404.2→290.3 (Pi-LAC) and m/. z 611.3→423.2 (candesartan cilextetil, the internal standard), respectively. The calibration curve of Pi and Pi-LAC in both human plasma and urine showed good linearity over the concentration range of 0.1-200. ng/mL. The established methods were successfully applied to a pharmacokinetic study of pitavastatin calcium tablets in healthy Chinese volunteers after oral administration of 1, 2 and 4. mg single and multiple doses of pitavastatin calcium. The pharmacokinetic parameters of Pi and Pi-LAC in Chinese volunteers were given respectively. The urinary excretion profiles of Pi and Pi-LAC in Chinese volunteers were also presented. After receiving a single 4. mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.
机译:有时,血浆中的药物及其代谢物可能会相互转化。这种现象称为互转换,可能会导致血浆样品不稳定的问题。由于共存代谢物相互转化而引起的不稳定性问题通常可以忽略不计,因为在准备用于方法验证的质量控制样品中没有药物代谢物。匹伐他汀(Pi)的主要代谢物匹伐他汀内酯(Pi-LAC)非常不稳定,在血浆中容易转化为Pi。本文开发了一种简单,快速的LC-ESI-MS / MS方法,用于同时测定人血浆和尿液中的Pi和Pi-LAC。在不同条件下检查样品的稳定性。通过将pH 4.2缓冲溶液添加到新鲜收集的血浆样品中,可以防止Pi和Pi-LAC的相互转化。通过以正离子多反应监测模式运行的电喷雾电离(ESI),通过监测从m /开始的离子跃迁进行检测。 z 422.2→290.3(Pi),404.2→290.3(Pi-LAC)和m /。分别为611.3→423.2(坎地沙坦cilextetil,内标)。 Pi和Pi-LAC在人血浆和尿液中的校准曲线在0.1-200的浓度范围内均显示出良好的线性。 ng / mL。所建立的方法在口服1、2和4 mg单剂量和多次剂量的匹伐他汀钙后,已成功地应用于健康的中国志愿者中匹伐他汀钙片的药代动力学研究。分别给出了Pi和Pi-LAC在中国志愿者体内的药代动力学参数。还介绍了中国志愿者中Pi和Pi-LAC的尿排泄情况。接受单剂量口服匹伐他汀钙4. mg后,中国志愿者中Pi和Pi-LAC的平均累积尿排泄百分比分别为(0.41±0.16)%和(6.1±5.0)%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号